

Glossopharyngeal Neuralgia: A Comprehensive Update

Shamimul Hasan¹, Rajat Panigrahi², Sk. Tarique Ajiz³

¹Professor, Department of Oral Medicine and Radiology, Faculty of Dentistry, Jamia Millia Islamia, New Delhi, ²Associate Professor, Department of Oral Medicine and Radiology, Institute of Dental Sciences, Siksha O Anusandhan (Deemed to be University), Bhubaneswar, Odisha, India, ³Project Officer, International Institute for Population Sciences, Mumbai, Maharashtra, India

Abstract

Glossopharyngeal neuralgia (GN) is an unusual clinical condition where severe paroxysmal pain of the glossopharyngeal nerve. GN pain should be differentiated from trigeminal neuralgia pain, as the two neuralgias share several similar features. Thorough medical history coupled with a detailed clinical examination and hematologic and radiographic investigations is necessary for early and accurate diagnosis. Anticonvulsants form the cornerstone of the medical management, and surgical interventions (microvascular decompression and gamma knife surgery) is needed in cases resistant to pharmacotherapy.

Keywords: Carbamazepine, glossopharyngeal neuralgia, microvascular decompression, neuralgia.

Introduction

Neurologica non-nociceptive pain or pain which does not relate to the activation of pain receptor cells in the body. It's a type of pain due to a lesion or any disorder of the somatosensory system.¹

As per ICHD-3 (International Classification of Headache Disease-3) classification, glossopharyngeal neuralgia (GN) is a disorder characterized by a brief periodic unilateral pain, with sharp and piercing in character, with abrupt onset and cessation, in the glossopharyngeal nerve distribution (angle of the jaw, ear, tonsillar fossa and the tongue base). It falls under the International Classification of Diseases (ICD) category as ICD-10-CM-G52.^{1 2}

The International Association for the Study of Pain (IASP) defines it as sudden, severe, brief, recurrent pain along the glossopharyngeal nerve distribution.³

GN is an extremely uncommon occurrence and accounts for only 0.2%–1.3% of the cases with facial pain.^{4,5} GN usually affects the male individuals above 50 year-age, and the reported incidence of GN is roughly 0.8 per 100,000 persons per year.^{4,6-11}

It must be asserted that GN is not as rare as reported in the literature due to non-familiarity with the disease, diagnostic obstacles, and more so with the escalating number of patients with Eagle's syndrome.¹²

Historical Background: Theodore H. Weisenburg (1910) was the first to provide the classic description of GN in a patient who reported with a lancinating ear and neck. Autopsy reports revealed that the pain was due to a cerebellopontine angle tumor, which presses the trigeminal nerve and stretches the glossopharyngeal nerve.¹³

After 10 yrs in 1920, Sicard and Robineau (1920) reported 3 patients with "Algie Velo-pharyngee essentielle" i.e. Pain along the distribution of glossopharyngeal nerve idiopathically^{10,13}

Corresponding Author:

Rajat Panigrahi

Associate Professor, Department of Oral Medicine and Radiology, Institute of Dental Sciences, Siksha O Anusandhan (Deemed to be University), Bhubaneswar, Odisha, India
e-mail: drrajat@gmail.com

The term “glossopharyngeal neuralgia” was framed by Wilfred Harris. He described GN as a painful condition characterized by episodes of severe lancinating, unilateral pain along the nerve division, which may be triggered by trigger point stimulation in areas supplied by the nerve.^{10,13}

Two noteworthy advancements were reported for the efficient management of glossopharyngeal neuralgia in 1927. J. Doyle published a case series of 18 GN patients, and W. Dandy performed the first successful intracranial resection for glossopharyngeal neuralgia.¹⁴

Riley et al. (1942) reported an uncommon association of GN with life-threatening cardiovascular manifestations- asystole, transient/persistent bradycardia, syncopal episodes, and even seizures.⁸

Classification:

1. Based on the International Headache Society (IHS) Classification, GP is classified as (1) classical GPN (occasional or episodic pain) and (2) symptomatic GPN (persistent pain; persisting between the episodes of peaks and troughs of pain).¹⁵
2. Based on the pain distribution, GN is classified as- (a) Otitic pain: Pain in (or around) the auricle/ear lobe (b) Oropharyngeal pain: Pain of neck and maxillofacial regions. Nevertheless, these regions show considerable overlap in the cranial nerve-supplied areas.¹⁶
3. Based on the causal factors, GN is classified as (a) Idiopathic/essential GN- The majority of GN cases are idiopathic, where no apparent lesion is noticed.¹⁷ GN is caused by neurovascular compression of nerve IX by the postero-inferior cerebellar artery (PICA),¹⁸ which was first observed postmortem by Brihaye et al.¹⁹ (b) Secondary GN- where a demonstrable lesion is seen. Eagle’s syndrome/stylogia accounts for the most common secondary cause of GN.¹³

Eagle’s syndrome is an unusual disorder, clinically larger in size of the styloid process or stylohyoid ligament complex is mineralized.

Clinical Features: Glossopharyngeal neuralgia is a rare disease entity, characterized by pain paroxysms in the regions supplied by the glossopharyngeal nerve (auricular and pharyngeal). The GN pain is typically characterized as brief episodes of unilateral severe, piercing/lancinating pain, confined primarily of the ear,

ventral surface of tongue, throat, tonsillar region, or beneath the angle of the jaw.²¹

The GN pain distribution is diagnostic: The pain generally commences from the pharyngeal, tonsillar, and posterior base of tongue and includes the eustachian tube and inner ear or spreads to the mandibular angle. Exacerbating factor in GN is generally deglutition, and cold liquids mainly evoke the pain.²¹

GN pain is transient and excruciating to begin with (lasts for 30sec), although it may recur after days, weeks/months and persists in the same areas.^{22,23} Swallowing, chewing, sneezing, talking, cleaning the throat, and light touch to the gums/oral mucosa, abrupt head movements, pain on lifting of the arm of the effected site, and the lateral jaw movement may also precipitate the pain.²⁴

Vagotossopharyngeal neuralgia refers to an uncommon linkage between GN and syncope,² where the affected individual presents with episodes of bradycardia, severe hypotension, syncope, and even cardiac arrest.²⁵ The probable reason for these life-threatening manifestations in GN may be attributed to the anatomical vicinity of glossopharyngeal nerve with the vagus and nervus intermedius.²⁶

It is important to distinguish GN from trigeminal neuralgia (TGN), that shares some features with GN and can combined form in 10% of patients.²⁷ Spontaneous remission is seen in both GN and TGN.⁸

GN is an uncommon clinical entity as compared to TGN (Reported prevalence rate of GN and TGN is approximately 0.8/100,000 population and 4.7/100,000 population respectively).⁹ The left side of the face is usually affected in GN in contrast to the right side in TGN.²⁸

The two neuralgias can also be differentiated based on the site affected and triggering factors. GN has the predilection for the throat and tonsillar region, and TGN primarily affects cheek, ala of nose, vermilion border of lips (facial region along the trigeminal nerve division). GN pain is triggered by chewing and swallowing, whereas, a light facial touch while washing/brushing the teeth exacerbates the TGN pain.¹⁶

A dull ache usually persists between pain episodes in GN,²⁹ in contrast to symptom-free periods between pain paroxysms in TGN. Any individual experiencing a dull ache between pain paroxysm does not fulfill TGN diagnostic criteria.³⁰

GN pain occurs mostly during the daytime, but the pain may disturb the sleep and the patient may wake up in the night. However, there is no pain during sleep in TGN.²⁹ Topical anesthetic application on pharyngeal mucosa may relieve GN pain, thus, distinguishing it from other neuralgias. Vasoglossopharyngeal neuralgia may be associated with life-threatening cardiovascular features- syncope, hypotension, cardiac arrhythmias, in contrast to trigeminal neuralgia.²⁹

Diagnostic Aids: Characteristic clinical manifestations usually suffice for the diagnosis of GN, and definitive investigative tests do not exist. GN patients are usually recommended for an ear, nose, and throat (ENT) consultation to rule out a possible anatomical lesion.² The distinctive unilateral, severely piercing, episodic pain in the throat, triggered on swallowing provides confirmation for GN pain, and differentiates it from the pain of inflammatory origin (constant pain, lasts for minutes). Glossopharyngeal nerve involvement/ association with other cranial nerves may be evaluated by assessing the pain distribution. Ototic pain may be detected by injecting an anesthetic solution (2% Lignocaine or 0.5% bupivacaine) into the region with a close approximation to the trigger point.¹¹ Potential etiologies such as vascular compression/neoplasms may be demonstrated by radiographic evaluation of the brain stem. A high-resolution neck CT scan may demonstrate Eagle's syndrome.²

Treatment: GN may be treated with either Pharmacologic/non-pharmacologic interventions.³¹

Carbamazepine is regarded as the drug of choice in GN. The drug has an inhibitory action on the brain stem reflex activity.³² Also, the drug has a possible action on preventing bradycardia.^{33,34}

Gabapentin, pregabalin, and lamotrigine are the other pharmacotherapeutic agents used in GN. Gabapentin and pregabalin act on the $\alpha_2\delta$ subunit of calcium channels, and diminish the release of excitatory neurotransmitters. Anticholinergic therapy, β_2 -adrenoceptor agonists (atropine, isoprenaline) and temporary pacing may be used to manage the bradyarrhythmia in GN.³⁵ Published literature has also elucidated the efficacy of selective serotonin reuptake inhibitors (20–50mg/day paroxetine and 50–200mg/day sertraline) and vitamin B12 in the management of GN.³⁶

Only a few cases of GN have shown response to non-steroidal anti-inflammatory drugs (due to their

probable action on unidentified acute inflammation) and opioids (as an ancillary agent to the anti-convulsants).¹⁷

Glossopharyngeal nerve block provides quick pain amelioration and acts as an excellent ancillary aid in the medical management of GN. It will be done with either (local anesthetic agents) non-neurolytic agents with or without additions of (steroid, ketamine, etc.) or with (phenol, alcohol, glycerol, etc.) neurolytic agents.³⁷

Surgical management is usually adopted in young aged, recalcitrant cases and is associated with high morbidity.¹⁷

Microvascular decompression (MVD) is the most preferred surgical technique associated with the highest success rates.²⁸ MVD is a more efficient treatment than Gamma knife surgery (GKS) due to both initial and long-term pain remission, lower relapse rates, and maintaining a pain-free status.³⁸

Conclusion

Glossopharyngeal neuralgia is an uncommon neuropathic pain that occurs along the distribution of the glossopharyngeal nerve. GN can be classified based on the nature of pain, site predilection, and etiologic factors. This neuralgic pain mimics trigeminal neuralgia; hence, an early and accurate diagnosis is mandatory. The condition is seldom associated with life-threatening cardiovascular manifestations like bradycardia, hypotension, syncope and rarely cardiac arrest. Pharmacotherapy with anti-convulsants is usually sufficient, although surgical intervention may be required in resistant cases.

Conflict of Interests: None

Ethical Permission: Approved

Funding: Nil

References

1. Jensen TS, Baron R, Haanpää M, Kalso E, Loeser JD, Rice AS, et al. A new definition of neuropathic pain. *Pain*. 2011;152:2204–05.
2. Blumenfeld A, Nikolskaya G. Glossopharyngeal neuralgia. *Curr Pain Headache Rep*. 2013;17(7):343.
3. International Association for the Study of Pain. Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. *Pain Suppl*. 1986;3:S1–226.

4. Chawla JC, Falconer MA. Glossopharyngeal and vagal neuralgia. *Br Med J* 1967;3:529–531.
5. Fraioli B, Esposito V, Ferrante L, Trubiani L, Lunardi P. Microsurgical treatment of glossopharyngeal neuralgia: case reports. *Neurosurgery* 1989;25: 630–632.
6. Manzoni GC, Torelli P. Epidemiology of typical and atypical craniofacial neuralgias. *Neurol Sci* 2005;26:s65–s67.
7. Katusic S, Williams DB, Beard CM, Bergstralh E, Kurland LT. Incidence and clinical features of glossopharyngeal neuralgia, Rochester, Minnesota, 1945-1984. *Neuroepidemiology* 1991;10:266–275.
8. Rushton JG, Stevens JC, Miller RH. Glossopharyngeal (vagoglossopharyngeal) neuralgia: a study of 217 cases. *Arch Neurol* 1981;38:201–205.
9. Koopman JSHA, Dieleman JP, Huygen FJ, de Mos M, Martin CGM, Sturkenboom MCJM. Incidence of facial pain in the general population. *Pain* 2009;147: 122–127.
10. Pearce JMS. Glossopharyngeal neuralgia. *Eur Neurol* 2006;55:49–52.
11. Patel A, Kassam A, Horowitz M, Chang Y-F. Microvascular decompression in the management of glossopharyngeal neuralgia: analysis of 217 cases. *Neuro-surgery* 2002;50:705–710.
12. Olds MJ, Woods CI, Winfield JA. Microvascular decompression in glossopharyngeal neuralgia. *Am J Otol.* 1995;16:326–30.
13. Soh KBH. The glossopharyngeal nerve, glossopharyngeal neuralgia and the Eagle's syndrome - current concepts and management. *Singap. Med. J.* 1999;40(10):659–65.
14. Peet MM. Glossopharyngeal neuralgia. *Ann. Surg.* 1935 Jan;101(1):256-68.
15. Headache classification committee of the international headache society (IHS), "The international classification of headache disorders," *Cephalalgia* 2004;24(9)
16. Teixeira MJ, Siqueira RDT, Shu EBS. Glossopharyngeal neuralgia: Neurosurgical treatment and differential diagnosis. *Acta Neurochirurgica* 2008;150(5):471–75.
17. Singh PM, Kaur M, Trikha A. An uncommonly common: Glossopharyngeal neuralgia. *Ann Indian Acad Neurol.* 2013;16(1):1–8.
18. Gaul C, Hastreiter P, Duncker A, Naraghi R. Diagnosis and neurosurgical treatment of glossopharyngeal neuralgia: clinical findings and 3-D visualization of neurovascular compression in 19 consecutive patients. *J Headache Pain* 2011;12:527–34.
19. Brihaye J, Perier O, Smulders J, Franken L. Glossopharyngeal neuralgia caused by compression of the nerve by an atheromatous vertebral artery. *J Neurosurg* 1956;13:299–302.
20. Hasan S. Eagles Syndrome: A Current Update. *Acta Scientific Dental Sciences.* 2018;2(50):49-52.
21. Alafaci C, Granata F, Cutugno M, Marino D, Conti A, Tomasello F. Glossopharyngeal neuralgia caused by a complex neurovascular conflict: Case report and review of the literature. *Surg Neurol Int.* 2015;6:19.
22. Kerr AG, Stephens D, editors. In Scott Brown's Otolaryngology. Fifth edition. Oxford: Butterworth Heinemann; 1987. Patten JP: Basic Sciences; pp. 379–407.
23. Webb CJ, Makura ZG, McCormick MS. Glossopharyngeal neuralgia following foreign body impaction in the neck. *J Laryngol Otol.* 2000;114:70–2.
24. Bruyn GW. Glossopharyngeal neuralgia. *Cephalalgia.* 1983;3:143–57.
25. Barbash GI, Keren G, Korczyn AD et al. Mechanisms of syncope in glossopharyngeal neuralgia. *Electroencephalogr Clin Neurophysiol* 1986;63:231–35.
26. Ozenci M, Karaoguz R, Conkbayir C, Altin T, Kanpolat Y. Glossopharyngeal neuralgia with cardiac syncope treated by glossopharyngeal rhizotomy and microvascular decompression *Europace.* 2003;5:149–52.
27. Rozen TD. Trigeminal neuralgia and glossopharyngeal neuralgia. *Neurol Clin* 2004;22:185–206.
28. Rey-Dios R, Cohen-Gadol AA. Current neurosurgical management of glossopharyngeal neuralgia and technical nuances for microvascular decompression surgery. *Neurosurg Focus.* 2013;34(3):E8.
29. Greenberg MS, Glick M, Ship J. *Burket's Oral Medicine Diagnosis and Treatment* 11th ed. New York: BC Decker 2008.

30. Hasan S, Khan NI, Sherwani OA, Bhatt V, Asif S. Trigeminal neuralgia: An Overview of literature with emphasis on medical management. *International Research Journal of Pharmacy* 2012;3(11):235-38.
31. Ferrante L, Artico M, Nardacci B, Fraioli B, Cosentino F, Fortuna A. Glossopharyngeal neuralgia with cardiac syncope. *Neurosurgery* 1995;36: 58–63.
32. Evans RW, Torelli P, Manzoni GC. Glossopharyngeal neuralgia. *Headache* 2006;46:1200–1202.
33. Jacobson RR, Russell RW. Glossopharyngeal neuralgia with cardiac arrhythmia: a rare but treatable cause of syncope. *Br Med J* 1979;1:379–380.
34. Kim SS, Lal R, Ruffly R. Bradycardic and vasodepressor syncope secondary to glossopharyngeal neuralgia from hypopharyngeal tumor. *Am Heart J* 1985;109: 1101–1102.
35. Hartog AWD, Jansen E, Kal JE, Duyndam D, Jeldican Visser J, Pepijn van den Munckhof PVD et al. Recurrent syncope due to glossopharyngeal neuralgia. *Heart Rhythm Case Reports*. 2017;3(1):73-77.
36. Khan M, Nishi SE, Hassan SN, Islam MA, Gan SH. Trigeminal Neuralgia, Glossopharyngeal Neuralgia, and Myofascial Pain Dysfunction Syndrome: An Update. *Pain Res Manag*. 2017;2017:7438326
37. Bean-Lijewski JD. Glossopharyngeal nerve block for pain relief after pediatric tonsillectomy. *Anesth Analg*. 1997; 84:1232–38.
38. Barletta EA, Cavuto CC, Gaspar RHML, Araújo JFM, Neves MWF, Aquino JLBD et al. Treatment of Trigeminal and Glossopharyngeal Neuralgia: A Comparison between the Outcome of the Microvascular Decompression and the Gamma Knife Radiosurgery. *EC Neurology* 2018;10(7): 600-604.